2,4-二氟苯丙酮 | 274682-91-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-二氟苯丙酮
• 中文别名: 1-(2,4-二氟苯基)丙-2-酮
• 英文名称: 1-(2,4-difluorophenyl)propan-2-one
• CAS: 274682-91-6
• 化学式: C₉H₈F₂O
• 分子量: 170.159
• InChiKey: XVHHDTNIOCSTLH-UHFFFAOYSA-N

物化性质

• 沸点：
  201.3±25.0 °C(Predicted)
• 密度：
  1.179±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 安全说明：
  S24/25
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存放于0至6℃阴凉干燥处。

SDS

Name:	2 4-Difluorophenylacetone 98% Material Safety Data Sheet
Synonym:
CAS:	274682-91-6

Section 1 - Chemical Product MSDS Name:2 4-Difluorophenylacetone 98% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
274682-91-6	2,4-Difluorophenylacetone	98%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 274682-91-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Clear liquid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H8F2O
Molecular Weight: 170.16

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 274682-91-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,4-Difluorophenylacetone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 274682-91-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 274682-91-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 274682-91-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,4-二氟苯丙酮 在 哌啶 、 C₃₇H₅₆N₄O₄ 、 potassium carbonate 、 溶剂黄146 、 cobalt(II) chloride 、 scandium tris(trifluoromethanesulfonate) 作用下， 以 四氢呋喃 、 甲醇 、 水 、 异丙醇 、 乙腈 为溶剂， 反应 60.33h， 生成 (2R,3R)-2-(2,4-二氟苯基)-1-(1H-1,2,4-三唑-1-基)丁烷-2,3-二醇
  参考文献：
  名称：

  末端烯酮的不对称催化环氧化合成三唑类抗真菌剂

  摘要：

  实现了α-取代乙烯基酮的对映选择性环氧化，构建了合成各种三唑类抗真菌剂的关键环氧化物中间体。通过使用手性N,N'-二氧化物/Sc III配合物作为手性催化剂和 35% 的水溶液，该反应以高产率和良好的对映选择性有效进行。H 2 O 2作为氧化剂。它使光学活性艾沙康唑、依氟康唑和其他潜在的抗真菌剂的转化成为可能。

  DOI：

  10.1021/acs.orglett.1c02588
• 作为产物：
  描述：

  乙酸异丙烯酯 、 2,4-二氟苯胺 在 硫酸 、 sodium nitrite 、 copper(ll) sulfate pentahydrate 、 sodium sulfite 作用下， 以 水 为溶剂， 反应 4.0h， 生成 2,4-二氟苯丙酮
  参考文献：
  名称：

  末端烯酮的不对称催化环氧化合成三唑类抗真菌剂

  摘要：

  实现了α-取代乙烯基酮的对映选择性环氧化，构建了合成各种三唑类抗真菌剂的关键环氧化物中间体。通过使用手性N,N'-二氧化物/Sc III配合物作为手性催化剂和 35% 的水溶液，该反应以高产率和良好的对映选择性有效进行。H 2 O 2作为氧化剂。它使光学活性艾沙康唑、依氟康唑和其他潜在的抗真菌剂的转化成为可能。

  DOI：

  10.1021/acs.orglett.1c02588

文献信息

• [EN] NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION<br/>[FR] DÉRIVÉS D'ACIDE NAPHTALÈNE ACÉTIQUE CONTRE L'INFECTION PAR LE VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2013103738A1

  公开（公告）日：2013-07-11

  The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein.

  该发明提供了作为d的化合物及其盐。该发明还提供了包括本文所披露的化合物的药物组合物，用于制备本文所披露的化合物的过程，用于制备本文所披露的化合物的中间体，以及使用本文所披露的化合物治疗HIV感染、治疗HIV病毒的增殖、治疗艾滋病或延缓哺乳动物发生艾滋病或ARC症状的治疗方法。
• [EN] NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS<br/>[FR] DÉRIVÉS D'ACIDE NAPHT-2-YLACÉTIQUE DANS LE TRAITEMENT DU SIDA
  申请人：GILEAD SCIENCES INC

  公开号：WO2012003497A1

  公开（公告）日：2012-01-05

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).

  这项发明提供了如下式（I）的化合物或其盐。该发明还提供了包括如下式I的化合物的药物组合物，制备如下式（I）化合物的方法，用于制备如下式I化合物的有用中间体，以及使用如下式（I）化合物治疗HIV病毒的增殖、治疗艾滋病或延缓哺乳动物发生艾滋病或ARC症状的治疗方法。
• METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20150148542A1

  公开（公告）日：2015-05-28

  The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及根据本文所描述和定义的一般式（I）制备取代三唑吡啶化合物的方法，以及用于制备所述化合物的中间体化合物。
• Process for the preparation of strobilurin intermediates
  申请人：Bayer Aktiengesellschaft

  公开号：US06664422B1

  公开（公告）日：2003-12-16

  The present invention relates to a novel improved process and intermediates for the process of preparing the oxime intermediates of formula (II) wherein R1 is hydrogen, fluoro or chloro, and R2 is methyl, ethyl, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy, cyano, fluoro, chloro or bromo. The novel process comprises diazotizing an aniline of formula (VI) reacting the resulting diazonium salt with isopropenylacetate of formula (X) and reacting the resulting ketone of formula (XI) with an organic nitrite in the presence of hydrogene chloride, and methylating the resulting ketooxime of formula (VIII) with a methylating agent and reacting the resulting O-methyl ketooxime of formula (IX) with hydroxylamine. The compounds of formula (II) are intermediates for highly active fungicides from the class of the strobilurins.

  本发明涉及一种改进的新型工艺和工艺中间体，用于制备化合物的羟肟中间体（II），其中R1为氢、氟或氯，R2为甲基、乙基、甲氧基、乙氧基、三氟甲基、三氟甲氧基、氰基、氟、氯或溴。新型工艺包括将公式（VI）的苯胺重氮化，将得到的重氮盐与公式（X）的异丙烯酸酯反应，将得到的酮与有机亚硝酸酯在氯化氢存在下反应，以及用甲基化剂甲基化得到的酮羟肟（VIII），并将得到的O-甲基酮羟肟（IX）与羟肟反应。公式（II）的化合物是高活性杀菌剂的中间体，属于叠氮类杀菌剂。
• [EN] 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR<br/>[FR] DERIVES DE 4-ARYLSULPHONYLPIPERIDINE POUR L'ANTAGONISME DU RECEPTEUR DE 5-HT2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2004101518A1

  公开（公告）日：2004-11-25

  Compounds of formula (I): are selective antagonists of the 5-HT2A receptor, and hence are useful in treatment of adverse conditions at the central nervous system, such as sleep disorders and schizophrenia.

  式(I)的化合物是5-HT2A受体的选择性拮抗剂，因此在治疗中枢神经系统的不良症状，如睡眠障碍和精神分裂症方面具有用处。